Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Should Pharma Be Concerned About Cooling China-Korea Ties?

Executive Summary

Despite regional defense policy concerns that have prompted broad moves to limit economic exchanges between China and South Korea, which could also potentially affect ever expanding healthcare collaborations between the two countries, the pharma sector impact so far appears to be limited.

You may also be interested in...



Yuhan, Luoxin Deal Underscores Asian NSCLC Therapy Needs

Yuhan and Luoxin's licensing agreement for a third generation EGFR inhibitor, the second such deal between South Korea and China, suggests robust demand for novel drugs for non-small cell lung cancer in Asia.

China Biobetter EPO Deal Seen Boosting Genexine’s Prospects

Following deals last year in China and ASEAN, Genexine has now inked a $44.5m agreement with a subsidiary of Shanghai Fosun Pharmaceutical to license out a novel long-acting EPO for anemia. The deal is set to further buoy the South Korean bioventure’s global presence and beef up the Chinese firm’s pipeline.

Hanmi’s Roll Continues With ZAI China Cancer Deal

Hanmi is continuing to reap big dividends this year from its original R&D efforts. Following a major licensing out deal with Boehringer Ingelheim for a novel lung cancer therapy in July, the South Korean firm has now reached an additional licensing agreement for the therapy with ZAI Lab for China, Hong Kong and Macau, in a deal that will bolster the Chinese biopharma's growing oncology portfolio.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel